# MG1 Maraba/MAGE-A3, With and Without Adenovirus Vaccine With Transgenic MAGE-A3 Insertion in Incurable MAGE-A3-Expressing Solid Tumours

> **NCT02285816** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Canadian Cancer Trials Group** · enrollment: 56 (actual)

## Conditions studied

- Advanced/Metastatic Solid Tumours

## Interventions

- **BIOLOGICAL:** MG1MA3
- **BIOLOGICAL:** AdMA3

## Key facts

- **NCT ID:** NCT02285816
- **Lead sponsor:** Canadian Cancer Trials Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2015-01-22
- **Primary completion:** 2019-09-19
- **Final completion:** 2026-12-31
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2026-03-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02285816

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02285816, "MG1 Maraba/MAGE-A3, With and Without Adenovirus Vaccine With Transgenic MAGE-A3 Insertion in Incurable MAGE-A3-Expressing Solid Tumours". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02285816. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*